More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $106.10 |
|
|||
| Open | $106.39 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $107.72 | ||||
| Day Low | $106.05 | ||||
| P/E | 23.33 | ||||
| EPS | $4.61 | ||||
| Volume | 5,977,406 | ||||
- AbbVie (ABBV) Submits Regulatory Applications for SKYRIZI (risankizumab) in Psoriatic Arthritis to FDA and EMA
- AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
- AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
- RBC Capital Assumes Abbvie (ABBV) at Outperform
- AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Moderate to Severe Atopic Dermatitis
- AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
- Form 4 AbbVie Inc. For: Mar 31 Filed by: Alpern Robert J
- Form 4 AbbVie Inc. For: Mar 31 Filed by: LIDDY EDWARD M
- Form 4 AbbVie Inc. For: Mar 31 Filed by: RAPP EDWARD J
- SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
Entities mentioned with ABBV
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Morgan Stanley | View Related Stories »
- Goldman Sachs | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
